Kenneth Wilson - Dr Martens CEO Director
| DOCMF Stock | USD 0.72 0.02 2.86% |
Insider
Kenneth Wilson is CEO Director of Dr Martens plc
| Age | 56 |
| Phone | 44 12 1415 7047 |
| Web | https://www.drmartensplc.com |
Kenneth Wilson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kenneth Wilson against Dr Martens pink sheet is an integral part of due diligence when investing in Dr Martens. Kenneth Wilson insider activity provides valuable insight into whether Dr Martens is net buyers or sellers over its current business cycle. Note, Dr Martens insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dr Martens'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kenneth Wilson over six months ago Disposition of 2590 shares by Kenneth Wilson of Jabil Circuit at 135.11 subject to Rule 16b-3 | ||
Kenneth Wilson over a year ago Sale by Kenneth Wilson of 3193 shares of Jabil Circuit | ||
Kenneth Wilson over a year ago Payment of 9504 shares by Kenneth Wilson of Jabil Circuit subject to Rule 16b-3 | ||
Kenneth Wilson over a year ago Payment of 2383 shares by Kenneth Wilson of Jabil Circuit subject to Rule 16b-3 |
Dr Martens Management Efficiency
The company has return on total asset (ROA) of 0.1634 % which means that it generated a profit of $0.1634 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6446 %, meaning that it generated $0.6446 on every $100 dollars invested by stockholders. Dr Martens' management efficiency ratios could be used to measure how well Dr Martens manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| James Weinberg | Designer Brands | 62 | |
| William Combs | Weyco Group | N/A | |
| Keith Duplain | Caleres | N/A | |
| Thomas Lucas | Caleres | N/A | |
| Caspar Coppetti | On Holding | 47 | |
| Ronald Smith | American Rebel Holdings | 63 | |
| Martin Hoffmann | On Holding | 45 | |
| Curtis Esq | Rocky Brands | 77 | |
| John Kalinich | Deckers Outdoor | 56 | |
| Christina Stender | On Holding | N/A | |
| Suzy Cirulis | Caleres | N/A | |
| Mary Turner | Designer Brands | 66 | |
| Alex Griffin | On Holding | N/A | |
| Heidi ONeill | Nike Inc | 58 | |
| Bruce Thorn | Caleres | N/A | |
| W McGinnis | Caleres | 72 | |
| Yolanda Macias | Skechers USA | N/A | |
| Angela Bass | Caleres | 62 | |
| Deborah Ferre | Designer Brands | 70 | |
| Margaret Standing | Designer Brands | N/A | |
| Akihiko Sadaka | ASICS | N/A | |
Management Performance
| Return On Equity | 0.64 | |||
| Return On Asset | 0.16 |
Dr Martens plc Leadership Team
Elected by the shareholders, the Dr Martens' board of directors comprises two types of representatives: Dr Martens inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DOCMF. The board's role is to monitor Dr Martens' management team and ensure that shareholders' interests are well served. Dr Martens' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Martens' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meg Johnson, Chief Officer | ||
| Sue Gannon, Chief Officer | ||
| Emily Reichwald, G Sec | ||
| Lorenzo Moretti, Pres EMEA | ||
| Jon Mortimore, CFO Director | ||
| Kenneth Wilson, CEO Director | ||
| Sean ONeill, Chief Officer | ||
| Ronald Garricks, Chief Officer | ||
| Derek Chan, Pres APAC | ||
| Geert Peeters, Chief Officer |
DOCMF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Dr Martens a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.64 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 2.75 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 3.85 % | |||
| Shares Owned By Institutions | 69.40 % | |||
| Price To Earning | 33.56 X | |||
| Price To Book | 5.71 X |
Currently Active Assets on Macroaxis
Other Information on Investing in DOCMF Pink Sheet
Dr Martens financial ratios help investors to determine whether DOCMF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOCMF with respect to the benefits of owning Dr Martens security.